TrialJAMA2020

Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.

Giancarlo Natalucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.